Quarterly report pursuant to Section 13 or 15(d)

Commitments And Contingencies

v3.7.0.1
Commitments And Contingencies
6 Months Ended
Jun. 30, 2017
Commitments And Contingencies [Abstract]  
Commitments And Contingencies

14.Commitments and Contingencies

a)The Company has contracted with various vendors for research and development services, with terms that require payments over the terms of the agreements, usually ranging from two to 36 months. The costs to be incurred are estimated and are subject to revision. As of June 30, 2017, the total estimated cost to complete these agreements was approximately $8,500,000.  All of these agreements may be terminated by either party upon appropriate notice as stipulated in the respective agreements.

b)On June 22, 2009, the Company entered into a License Agreement with Korea Research Institute of Chemical Technology (“KRICT”) to acquire the rights to all intellectual property related to quinoxaline-piperazine derivatives that were synthesized under a Joint Research Agreement.  The initial license fee was $100,000, all of which was paid as of December 31, 2009.  The agreement with KRICT calls for a one-time milestone payment of $1,000,000 within 30 days after the first achievement of marketing approval of the first commercial product arising out of or in connection with the use of KRICT’s intellectual property.  As of June 30, 2017, the milestone has not occurred.

c)Office Space Lease

On June 5, 2009, the Company entered into a commercial lease agreement for 5,466 square feet of office space in Rockville, Maryland.  The lease was amended on June 7, 2013 to extend the term until June 30, 2019. 

On July 26, 2014 the lease was amended to add 1,727 square feet of office space for a term beginning on September 1, 2014 and ending on August 31, 2015, which was subsequently renewed for additional one-year terms, beginning on September 1, 2015 and 2016, and a 22-month term beginning September 1, 2017 and expiring on June 30, 2019. Under the lease agreement, the Company pays its allocable portion of real estate taxes and common area operating charges.

Rent paid under the Company’s lease during the three months ended June 30, 2017 and 2016 was $50,898 and $51,301, respectively, and rent paid during the six months ended June 30, 2017 and 2016 was $101,796 and $102,603, respectively.

Laboratory Lease

On April 20, 2015, the Company signed a five-year lease agreement for 2,552 square feet of laboratory space commencing on July 1, 2015 and ending on June 30, 2020.  Under the lease agreement, the Company pays its allocable portion of real estate taxes and common area operating charges. Rent paid under this lease during the three months ended June 30, 2017 and 2016 was $15,771 and $15,312, respectively, and rent paid during the six months ended June 30, 2017 was $31,543 and $30,624.

Future rental payments over the next five years for all leases are as follows:



 

 

 



 

 

 

For the remaining six months ending December 31:

2017

$

137,360 

For the year ending December 31:

2018

 

279,274 



2019

 

176,080 



2020

 

34,468 



 

 

 



Total

$

627,182 





d)The Company has established a 401(k) plan for its employees.  The Company has elected to match 100% of the first 3% of an employee’s compensation plus 50% of an additional 2% of the employee’s deferral. Expense related to this matching contribution aggregated to $34,606 and $31,587 for the three months ended June 30, 2017 and 2016, respectively, and $71,083 and $63,089 for the six months ended June 30, 2017 and 2016, respectively.

e)In July 2013, the Company entered into an exclusive license agreement with the University of Maryland, Baltimore for a novel drug delivery platform, Nano-Polymer Drug Conjugate Systems.  RX-21101 is the Company’s first drug candidate utilizing this platform.  The agreement requires the Company to make payments to the University of Maryland if RX-21101 or any products from the licensed delivery platform achieve development milestones.  As of June 30, 2017, no development milestones have occurred.

f)In October 2013, the Company signed an exclusive license agreement with the Ohio State Innovation Foundation, for a novel oligonucleotide drug delivery platform, Lipid-Coated Albumin Nanoparticle.  The agreement requires the Company to make payments to the Ohio State Innovation Foundation if any products from the licensed delivery platform achieve development milestones.  As of June 30, 2017, no development milestones have occurred.